High-Grade Glioma-Pipeline Review, H2 2017

High-Grade Glioma-Pipeline Review, H2 2017


  • Products Id :- GMDHC10016IDB
  • |
  • Pages: 333
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

High-Grade Glioma-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide High-Grade Glioma-Pipeline Review, H2 2017, provides an overview of the High-Grade Glioma (Oncology) pipeline landscape.

Highly grade gliomas (HGG) are tumors of the central nervous system (CNS) that arising from transformed cells of the brain and spinal cord. Symptoms include developmental delay, headaches, backaches, nausea and vomiting, dizziness, gait disturbances, impaired vision, lack of concentration, drowsiness, sleep disturbances, Dysregulated ap-petite, paralyses and seizures. Treatment includes Chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide High-Grade Glioma-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for High-Grade Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The High-Grade Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for High-Grade Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 15, 13 and 5 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 3 molecules, respectively.

High-Grade Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of High-Grade Glioma (Oncology).

The pipeline guide reviews pipeline therapeutics for High-Grade Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in High-Grade Glioma (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates High-Grade Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for High-Grade Glioma (Oncology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for High-Grade Glioma (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding High-Grade Glioma (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

High-Grade Glioma-Overview

High-Grade Glioma-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

High-Grade Glioma-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

High-Grade Glioma-Companies Involved in Therapeutics Development

AbbVie Inc

Advenchen Laboratories LLC

AngioChem Inc

Arog Pharmaceuticals Inc

Astellas Pharma Inc

Athenex Inc

Bayer AG

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Cavion LLC

CBT Pharmaceuticals Inc

Celgene Corp

Concordia International Corp

DelMar Pharmaceuticals Inc

Eisai Co Ltd

Ipsen SA

Karyopharm Therapeutics Inc

Millennium Pharmaceuticals Inc

Nektar Therapeutics

Northwest Biotherapeutics Inc

Novartis AG

Ono Pharmaceutical Co Ltd

Sanofi

Sorrento Therapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

Targepeutics Inc

Tocagen Inc

ZIOPHARM Oncology Inc

High-Grade Glioma-Drug Profiles 40

AdRTSIL-12-Drug Profile 40

afatinib dimaleate-Drug Profile

alisertib-Drug Profile

apatinib mesylate-Drug Profile

bendamustine hydrochloride-Drug Profile

BMX-001-Drug Profile 80

cabazitaxel-Drug Profile

CBT-101-Drug Profile

Cellular Immunotherapy for High-Grade Glioma-Drug Profile

Cellular Immunotherapy for Oncology-Drug Profile

Cellular Immunotherapy for Oncology-Drug Profile

crenolanib besylate-Drug Profile

dabrafenib mesylate-Drug Profile

dabrafenib mesylate + trametinib dimethyl sulfoxide-Drug Profile

DCVax-L-Drug Profile

depatuxizumab mafodotin-Drug Profile

dianhydrogalactitol-Drug Profile

elatipepimut-S + adegrapepimut-S-Drug Profile

etirinotecan pegol-Drug Profile

flucytosine + TBio-01-Drug Profile

flucytosine ER + vocimagene amiretrorepvec-Drug Profile

GB-13-Drug Profile

HSV-1716-Drug Profile

ipilimumab + nivolumab-Drug Profile

irinotecan hydrochloride-Drug Profile

irinotecan hydrochloride + TBio-02-Drug Profile

KX-02-Drug Profile

lenvatinib mesylate-Drug Profile

mibefradil dihydrochloride-Drug Profile

nivolumab-Drug Profile

ONC-206-Drug Profile

Oncolytic Virus for High-Grade Glioma and Melanoma-Drug Profile

paclitaxel trevatide-Drug Profile

pomalidomide-Drug Profile

porfimer sodium-Drug Profile

RRX-001-Drug Profile 280

selinexor-Drug Profile

sorafenib tosylate-Drug Profile 30

z-90099-Drug Profile

High-Grade Glioma-Dormant Projects

High-Grade Glioma-Discontinued Products

High-Grade Glioma-Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for High-Grade Glioma, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

List of Tables

Number of Products under Development for High-Grade Glioma, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

High-Grade Glioma-Pipeline by AbbVie Inc, H2 2017

High-Grade Glioma-Pipeline by Advenchen Laboratories LLC, H2 2017

High-Grade Glioma-Pipeline by AngioChem Inc, H2 2017

High-Grade Glioma-Pipeline by Arog Pharmaceuticals Inc, H2 2017

High-Grade Glioma-Pipeline by Astellas Pharma Inc, H2 2017

High-Grade Glioma-Pipeline by Athenex Inc, H2 2017

High-Grade Glioma-Pipeline by Bayer AG, H2 2017

High-Grade Glioma-Pipeline by Boehringer Ingelheim GmbH, H2 2017

High-Grade Glioma-Pipeline by Bristol-Myers Squibb Co, H2 2017

High-Grade Glioma-Pipeline by Cavion LLC, H2 2017

High-Grade Glioma-Pipeline by CBT Pharmaceuticals Inc, H2 2017

High-Grade Glioma-Pipeline by Celgene Corp, H2 2017

High-Grade Glioma-Pipeline by Concordia International Corp, H2 2017

High-Grade Glioma-Pipeline by DelMar Pharmaceuticals Inc, H2 2017

High-Grade Glioma-Pipeline by Eisai Co Ltd, H2 2017

High-Grade Glioma-Pipeline by Ipsen SA, H2 2017

High-Grade Glioma-Pipeline by Karyopharm Therapeutics Inc, H2 2017

High-Grade Glioma-Pipeline by Millennium Pharmaceuticals Inc, H2 2017

High-Grade Glioma-Pipeline by Nektar Therapeutics, H2 2017

High-Grade Glioma-Pipeline by Northwest Biotherapeutics Inc, H2 2017

High-Grade Glioma-Pipeline by Novartis AG, H2 2017

High-Grade Glioma-Pipeline by Ono Pharmaceutical Co Ltd, H2 2017

High-Grade Glioma-Pipeline by Sanofi, H2 2017

High-Grade Glioma-Pipeline by Sorrento Therapeutics Inc, H2 2017

High-Grade Glioma-Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017

High-Grade Glioma-Pipeline by Targepeutics Inc, H2 2017

High-Grade Glioma-Pipeline by Tocagen Inc, H2 2017

High-Grade Glioma-Pipeline by ZIOPHARM Oncology Inc, H2 2017

High-Grade Glioma-Dormant Projects, H2 2017

High-Grade Glioma-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

AbbVie Inc

Advenchen Laboratories LLC

AngioChem Inc

Arog Pharmaceuticals Inc

Astellas Pharma Inc

Athenex Inc

Bayer AG

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Cavion LLC

CBT Pharmaceuticals Inc

Celgene Corp

Concordia International Corp

DelMar Pharmaceuticals Inc

Eisai Co Ltd

Ipsen SA

Karyopharm Therapeutics Inc

Millennium Pharmaceuticals Inc

Nektar Therapeutics

Northwest Biotherapeutics Inc

Novartis AG

Ono Pharmaceutical Co Ltd

Sanofi

Sorrento Therapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

Targepeutics Inc

Tocagen Inc

ZIOPHARM Oncology Inc

select a license
Single User License
USD 2000 INR 138340
Site License
USD 4000 INR 276680
Corporate User License
USD 6000 INR 415020

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com